Most Recent
The six-week trial in four defamation cases brought by war veteran Ben Roberts-Smith has been pushed off because of restrictions on in-person hearings and the Attorney-General's decision to invoke national security law and cloak the proceedings in secrecy.
Generic drug maker Juno Pharmaceuticals has agreed to stopped planned sales of its cheap version of Millennium Pharmaceuticals anti-cancer medication Velcade in Australia as part of a settlement of its lawsuit alleging two patents covering the drug were invalid.
Fairfax Media has failed in its appeal of a judgment that found the publisher defamed Chinese-Australian businessman Dr Chau Chak Wing in a Sydney Morning Herald article that linked him to an international bribery scandal.
A court has allowed a bankruptcy trustee to drop an "extremely disadvantageous" litigation funding agreement, which provided the funder with an 85 per cent commission, previously signed to pursue a Perth-based engineering and construction company.
A former Norton Rose Fulbright partner has lost his bid to block King & Wood Mallesons and two barristers from representing the law firm in a long-running feud over his termination, with an appeals court calling his allegations against the legal team "unfounded and misconceived".
War veteran Ben Roberts-Smith has been denied access to evidence revealing the identity of confidential sources that leaked information concerning alleged war crimes in Afghanistan that were detailed in news articles at the centre of a defamation lawsuit.
Lawyers for Norton Rose Fulbright have flagged their “very real concerns” about further delays to a long-running dispute with a former partner, who has indicated the will try to appeal a ruling partially granting him leave to appeal a discovery decision in the case.
Generic drug maker Juno Pharmaceuticals and US-based Millennium Pharmaceuticals have reached an in-principle settlement in their trans-Pacific dispute over two patents covering breakthrough anti-cancer medication Velcade.
Pharmaceutical company Generic Health has told the Federal Court that, on advice from their solicitors, Otsuka and Bristol-Myers Squibb "deliberately" chose not to disclose their reasons for an admission in a long-running patent case over the anti-psychotic drug Abilify, which they are now seeking to withdraw.
Fairfax Media has challenged a judge's "gravely serious" suggestion that one of its journalists lied about a confidential source, during the first day of a two-day appeal hearing over a $280,000 defamation judgment awarded to Chinese-Australian businessman Chau Chak Wing.